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    New Year 2021 has come. On January 1, American 
Diabetes Association (ADA) has announced the new 
version of the standards of Medical Care in Diabetes-
2021 [1]. It has 16 chapters with 222 pages. Among 
them, chapter 12 was for the guideline of the diabetic 
patients with Older Adults. In the actual medical 
practice, many elderly diabetic patients have been 
increased and treated [2]. The usual medical 
management for elder diabetic patients requires an 
adequate assessment of medical, functional, 
psychological, and social aspects, which means bio-
psycho-social domains [3]. Then, the treatment 
guideline for them would be the most common 
problem. From the current situation, several useful 




    Firstly, Diabetes has been highly prevalent for the 
elderly population. In >65 years old, more than one-
quarter of adults show diabetic and one-half of them 
show prediabetes. Diabetic condition has a close 
relationship with geriatric syndromes, including 
cognitive impairment, depression, persistent pain, 
falls, urinary incontinence, and polypharmacy. These 
problems usually aggravate QOL and self-management 
(level B) [4]. 
 
    Lifestyle management included the recommendation 
of optimal nutrition and protein intake [5], aerobic 
activity, weight-bearing   exercise,  resistance  training. 
 
Abstract 
    American Diabetes Association (ADA) has announced the new version of the standards of Medical Care in 
Diabetes-2021. The guideline of the diabetic patients with Older Adults seems to be used for a wide range of 
clinical practice. Among them, several impressive comments were found, where “Once-daily basal insulin 
injection therapy is associated with minimal side effects and maybe a reasonable option in many elder 
patients”. Recent topic includes Dual Action of Liraglutide and insulin degludec (DUAL) studies, and Xultophy 
has shown beneficial efficacy. Consequently, the trend would be developed from multiple daily injection (MDI) 
method to once daily injection. 
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Furthermore, several intensive lifestyle interventions 
should be considered such as dietary changes, physical 
activity, and weight reduction about 5-7%. These can 
be beneficial on QOL [6], physical functioning and 
mobility [7], and cardiometabolic risk factor control 
[8] (level A). 
 
    Secondly, the crucial points of pharmacological 
therapy recommendations include i) select oral 
hypoglycemic agents (OHA) with low risk of 
hypoglycemia, ii) avoid overtreatment common in 
elder diabetic adults [9], iii) make simplification of 
complex regimens [10], iv) consider necessary costs of 
care and insurance coverage for developing therapeutic 
plans.  
 
    For OHA, metformin is the first-line agent, which 
can be safely provided when eGFR≧30ml/min/1.73m2. 
Dipeptidyl peptidase-4 inhibitor (DPP-4i) has a low 
reverse effect such as hypoglycemia but rather 
expensive [11]. Sodium 2 Glucose Cotransporter 2 
Inhibitors (SGLT2i) are beneficial for cardiovascular 
disease, heart failure, and CKD progression [12]. 
Glucagon-like peptide 1 receptor agonists (GLP-1Ra) 
are beneficial for patients with established 
cardiovascular disease [13]. Liraglutide Effect and 
Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results (LEADER) trial showed the improved 
outcomes when cases are >50 years with CVD (HR 
0.83) [14]. In contrast, cases >60 years with no CVD 
showed various adverse events observed, such as 
nausea, vomiting, and diarrhea (HR 1.20). 
 
    Thirdly, several beneficial treatment protocols 
concerning insulin therapy will be described [2]. 
1) Concerning the insulin therapy, rather a 
breakthrough comment was found. “Once-daily 
basal insulin injection therapy is associated with 
minimal side effects and maybe a reasonable 
option in many older patients“. Multiple daily 
injections (MDI) of insulin may be too complex 
for the older patient, who has already advanced 
complications, coexisting chronic illnesses, or 
impaired functional status. The insulin regimen is 
recommended to become more simply protocol. 
The Algorithm is shown for an adequate insulin 
regimen for older  T2DM.  Basal  insulins  include 
 
 
glargine U-100, U-300, detemir, degludec and 
human NPH [15]. For better glucose variability, 
titrate dose of basal insulin on average fasting 
fingerstick data over a week. The goal is 90-150 
mg/dL (5.0-8.3 mmol/L) [1]. 
2) An important comment is found for mealtime 
insulin. If mealtime insulin is >10 units/dose, 
decrease dose 50% and add noninsulin agents. If 
it is < 10 units/dose, discontinue mealtime 
insulin and add noninsulin agents. After that, 
adequate management includes the evaluation of 
the estimated glomerular filtration rate (eGFR). 
When eGFR is >45 mL/min/1.73m2, start 
metformin 500mg daily and increase dose every 
2 weeks. When eGFR is <45 mL/min/1.73m
2
, 
diabetic patient has been already on metformin, 
or metformin is not tolerated, proceed to the 
second-line OHA [16]. 
3) Some additional tips are included. When 
adjusting mealtime insulin, use simplified sliding 
scale. If premeal glucose >250 (<350) mg/dL, 
provide 2(4) units of short- or rapid-acting 
insulin. Stop sliding scale method when not 
needed daily [2]. 
 
    Fourthly, three patterns of patient status            
were classified, which are i) healthy, ii) 
complex/intermediate and iii) very complex/poor 
health [17]. Treatment goals of HbA1c, fasting glucose 
and blood pressure are shown as follows. 
1) Healthy: It shows intact cognitive and functional 
status with longer remaining life expectancy, 
where 7.0–7.5%, 80–130 mg/dL, 140/90 mmHg 
with statin (unless contraindicated or not 
tolerated). 
2) Complex/intermediate: It shows multiple 
coexisting chronic illnesses, mild-to-moderate 
cognitive impairment, hypoglycemia vulnerability 
and fall risk. The target points are 8.0%, 90–150 
mg/dL, 140/90 mmHg with statin (unless 
contraindicated or not tolerated). 
3) Very complex/poor health: It shows moderate-to 
severe cognitive impairment [18] or ADL 
impairments, associated with uncertain benefit 
for life expectancy. Avoid reliance on HbA1c 
value, and diabetic management is based on 
avoiding hypoglycemia and symptomatic
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hyperglycemia. The target goal includes 100-180 
mg/dL, 150/90 mmHg with the consideration of 
possible benefit with statin. For diabetic patients 
with mild cognitive impairment (MCI), the trial of 
intranasal insulin and metformin therapy had 
provided insights for future developing studies 
[19]. 
 
    From mentioned above, recent topic includes the 
changes from MDI method to once daily injection as 
possible. The background to this would be the spread 
of basal insulin and the clinical application of Zultophy 
as a combination of insulin and GLP-1Ra. It is Insulin 
Degludec/Liraglutide (IDegLira, Xultophy) which is a 
fixed-ratio combination (FRC) for convenient and 
useful clinical efficacy [20]. There were a series of Dual 
Action of Liraglutide and insulin degludec (DUAL) 
studies on Xultophy. DUAL ii Japan was conducted for 
phase 3a randomized treat-to-target trial for half year 
[21]. The results revealed that the mean HbA1c/weight 
reduction was 1.6%/1.5kg, respectively for 6 months. 
Another study for Xultophy (n=413) showed that 
HbA1c change for 6 months was -0.16% as basal HbA1c 
<9%, and -1.67% as basal HbA1c >9%, respectively 
[22]. Furthermore, BMI showed -0.46% for those with 
less than 30, and -0.75% for those 30 or more than 30. 
Authors have reported the effects of Xultophy for 
patients with diabetes and chronic renal failure 
[23,24]. The useful add-on therapy (AOT) to diabetes 
would be useful for future treatment for diabetes with 
the satisfaction of patients [25]. 
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